FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Donald Bunjes

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Treatment Outcome

Anatomy

Phenomena

Recurrence

Physiology

Graft Rejection

Co-author Network

Publications

TOP 3
Peter Dreger; Michael Hallek; Ute Hegenbart; Michael Kneba; Peter Paschka; Matthias Ritgen; Marianna Rossi; Christof Scheid; Norbert Schmitz; Andrea Schnaiter; Michael Stadler; Sebastian Böttcher; Andreas Bühler; Donald Bunjes; Raymonde Busch; Sascha Dietrich; Hartmut Döhner; Lutz Uharek; Matthias Zeis; Thorsten Zenz; Stephan Stilgenbauer
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Tim Pfeiffer; Christof Scheid; Michael Schleuning; Günter Schlimok; Susanne Schnittger; Karsten Spiekermann; Johanna Tischer; Jan Braess; Stefanie Buchholz; Gesine Bug; Donald Bunjes; Maximilian Christopeit; Arnold Ganser; Hildegard Greinix; Karl-Heinz Haude; Ernst Holler; Hans-Jochem Kolb; Jiri Mayer; Ralf G Meyer; Christoph Schmid
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
Frieder Keller; Donald Bunjes; Bertram Hartmann; Susanne Wiesner; Michael Schmitt
Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Donald Bunjes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter Dreger; Michael Hallek; Ute Hegenbart; Michael Kneba; Peter Paschka; Matthias Ritgen; Marianna Rossi; Christof Scheid; Norbert Schmitz; Andrea Schnaiter; Michael Stadler; Sebastian Böttcher; Andreas Bühler; Donald Bunjes; Raymonde Busch; Sascha Dietrich; Hartmut Döhner; Lutz Uharek; Matthias Zeis; Thorsten Zenz; Stephan Stilgenbauer
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Blood 2013;121(16):3284-8.
2013: Tim Pfeiffer; Christof Scheid; Michael Schleuning; Günter Schlimok; Susanne Schnittger; Karsten Spiekermann; Johanna Tischer; Jan Braess; Stefanie Buchholz; Gesine Bug; Donald Bunjes; Maximilian Christopeit; Arnold Ganser; Hildegard Greinix; Karl-Heinz Haude; Ernst Holler; Hans-Jochem Kolb; Jiri Mayer; Ralf G Meyer; Christoph Schmid
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
Haematologica 2013;98(4):518-25.
2012: Frieder Keller; Donald Bunjes; Bertram Hartmann; Susanne Wiesner; Michael Schmitt
Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation.
Annals of transplantation : quarterly of the Polish Transplantation Society 2012;17(4):52-8.
2011: Peter Kletting; Thomas Kull; Markus Luster; Sven N Reske; Donald Bunjes; Gerhard Glatting
Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
Medical physics 2011;38(5):2572-8.
2011: Anita Schmitt; Torsten Tonn; Dirk H Busch; Götz Ulrich Grigoleit; Hermann Einsele; Marcus Odendahl; Lothar Germeroth; Mark Ringhoffer; Simone Ringhoffer; Markus Wiesneth; Jochen Greiner; Detlef Michel; Thomas Mertens; Markus Rojewski; Martin Marx; Stephanie von Harsdorf; Hartmut Döhner; Erhard Seifried; Donald Bunjes; Michael Schmitt
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.
Transfusion 2011;51(3):591-9.
2010: Martin Bommer; Stephanie von Harsdorf; Hartmut Döhner; Donald Bunjes; Mark Ringhoffer
Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation.
Haematologica 2010;95(11):1969-72.
2010: Jochen Greiner; Anita Schmitt; Krzysztof Giannopoulos; Markus T Rojewski; Marlies Götz; Isabel Funk; Mark Ringhoffer; Donald Bunjes; Susanne Hofmann; Gerd Ritter; Hartmut Döhner; Michael Schmitt
High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.
Haematologica 2010;95(7):1191-7.
2010: Dominik Schneidawind; Anita Schmitt; Markus Wiesneth; Thomas Mertens; Donald Bunjes; Mathias Freund; Michael Schmitt
Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant.
Leukemia & lymphoma 2010;51(6):1055-62.
2010: Peter Kletting; Thomas Kull; Donald Bunjes; Bettina Mahren; Markus Luster; Sven N Reske; Gerhard Glatting
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(3):484-91.
2010: Fei Fei; Yingzhe Yu; Anita Schmitt; Markus T Rojewski; Baoan Chen; Jochen Greiner; Marlies Götz; Donald Bunjes; Michael Schmitt
Effects of nilotinib on regulatory T cells: the dose matters.
Molecular cancer 2010;9():22.
2009: Andreas Schreiber; Georg Härter; Axel Schubert; Donald Bunjes; Thomas Mertens; Detlef Michel
Antiviral treatment of cytomegalovirus infection and resistant strains.
Expert opinion on pharmacotherapy 2009;10(2):191-209.
2009: Peter Kletting; Donald Bunjes; Sven N Reske; Gerhard Glatting
Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(2):296-302.
2009: Fei Fei; Yingzhe Yu; Anita Schmitt; Markus T Rojewski; Baoan Chen; Marlies Götz; Hartmut Döhner; Donald Bunjes; Michael Schmitt
Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
British journal of haematology 2009;144(2):195-205.
2008: Andreas K Buck; Martin Bommer; Malik E Juweid; Gerhard Glatting; Stephan Stilgenbauer; Felix Mottaghy; Melanie Schulz; Thomas Kull; Donald Bunjes; Peter Möller; Hartmut Döhner; Sven N Reske
First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(11):1756-62.
2008: Fabio Ciceri; Myriam Labopin; Franco Aversa; Jakob M Rowe; Donald Bunjes; Philippe Lewalle; Arnon Nagler; Paolo Di Bartolomeo; João F Lacerda; Maria Teresa Lupo Stanghellini; Emmanuelle Polge; Francesco Frassoni; Massimo F Martelli; Vanderson Rocha
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.
Blood 2008;112(9):3574-81.
2008: Fei Fei; Yingzhe Yu; Anita Schmitt; Markus T Rojewski; Baoan Chen; Jochen Greiner; Marlies Götz; Philippe Guillaume; Hartmut Döhner; Donald Bunjes; Michael Schmitt
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Experimental hematology 2008;36(10):1297-308.
2008: Jinfei Chen; Anita Schmitt; B Chen; Markus T Rojewski; V Rübeler; F Fei; Y Yu; X Yu; Mark Ringhoffer; Stephanie von Harsdorf; Jochen Greiner; M Götzz; P Guillaume; H Döhner; Donald Bunjes; Michael Schmitt
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
Journal of cellular and molecular medicine 2008;12(5B):2107-18.
2008: Norbert Grulke; Donald Bunjes; Wolfgang Larbig; Horst Kächele; Harald Bailer
Physicians' prognostic estimates of survival for patients undergoing allogeneic hematopoietic stem cell transplantation.
Journal of psychosomatic research 2008;65(1):61-6.
2008: Junxia Yao; Clemens Bechter; Markus Wiesneth; Georg Härter; Marlies Götz; Lothar Germeroth; Philippe Guillaume; Ferishte Hasan; Stephanie von Harsdorf; Thomas Mertens; Detlef Michel; Hartmut Döhner; Donald Bunjes; Michael Schmitt; Anita Schmitt
Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(10):e96-105.
2008: Michael Schmitt; Anita Schmitt; Markus T Rojewski; Jinfei Chen; Krzysztof Giannopoulos; Fei Fei; Yingzhe Yu; Marlies Götz; Marta Heyduk; Gerd Ritter; Daniel E Speiser; Sacha Gnjatic; Philippe Guillaume; Mark Ringhoffer; Richard F Schlenk; Peter Liebisch; Donald Bunjes; Hiroshi Shiku; Hartmut Dohner; Jochen Greiner
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Blood 2008;111(3):1357-65.
2007: Jinfei Chen; Anita Schmitt; Krzysztof Giannopoulos; Baoan Chen; Markus T Rojewski; Hartmut Döhner; Donald Bunjes; Michael Schmitt
Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.
International journal of oncology 2007;31(5):1133-9.
2007: Jinfei Chen; Anita Schmitt; Baoan Chen; Markus T Rojewski; Mark Ringhoffer; Stephanie von Harsdorf; Jochen Greiner; Philippe Guillaume; Hartmut Döhner; Donald Bunjes; Michael Schmitt
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Cancer immunology, immunotherapy : CII 2007;56(6):849-61.
2007: Lutz Von Müller; J Hinz; Martin Bommer; Walter Hampl; S Kluwick; M Wiedmann; Donald Bunjes; Thomas Mertens
CMV monitoring using blood cells and plasma: a comparison of apples with oranges?
Bone marrow transplantation 2007;39(6):353-7.
2007: Anja Dankerl; Peter Liebisch; Gerhard Glatting; Claudia Friesen; Norbert M Blumstein; Darius Kocot; Christiane Wendl; Donald Bunjes; Sven N Reske
Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
Radiology 2007;242(2):498-508.
2007: Mark Ringhoffer; Stephanie von Harsdorf; Michael Schmitt; Markus Wiesneth; Thorsten Zenz; Stephan Stilgenbauer; Jochen Greiner; Konstanze Döhner; Martin Marx; Hartmut Döhner; Donald Bunjes
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
British journal of haematology 2007;136(1):127-30.
2007: A-L Herr; Myriam Labopin; D Blaise; N Milpied; M Potter; M Michallet; W Heit; F Ferrara; J Esteve; W Arcese; G Ehninger; J M Rowe; Guido Kobbe; A Rosselet; Donald Bunjes; Bernard Rio; M Brune; A Nagler; N C Gorin; F Frassoni; V Rocha
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.
Leukemia 2007;21(1):129-35.
2006: Andreas K Buck; Martin Bommer; Stephan Stilgenbauer; Malik E Juweid; Gerhard Glatting; Holger Schirrmeister; Torsten Mattfeldt; Djurdja Tepsic; Donald Bunjes; Felix Mottaghy; Bernd J Krause; Bernd Neumaier; Hartmut Döhner; Peter Möller; Sven N Reske
Molecular imaging of proliferation in malignant lymphoma.
Cancer research 2006;66(22):11055-61.
2006: Thorsten Zenz; Matthias Ritgen; Peter Dreger; Alexander Kröber; Thomas F E Barth; Richard F Schlenk; Sebastian Böttcher; Michael Hallek; Michael Kneba; Donald Bunjes; Hartmut Döhner; Stephan Stilgenbauer
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Blood 2006;108(6):2127-30.
2006: Gerhard Glatting; Marguerite Müller; Bernd Koop; Kathrin Hohl; Claudia Friesen; Bernd Neumaier; Eleanor Berrie; Pru Bird; Geoff Hale; Norbert M Blumstein; Herman Waldmann; Donald Bunjes; Sven N Reske
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(8):1335-41.
2006: Christoph Schmid; Michael Schleuning; Rainer Schwerdtfeger; Bernd Hertenstein; Eva Mischak-Weissinger; Donald Bunjes; Stephanie von Harsdorf; Christoph Scheid; Udo Holtick; Hildegard Greinix; Felix Keil; Barbara Schneider; Michael Sandherr; Gesine Bug; Johanna Tischer; Georg Ledderose; Michael Hallek; Wolfgang Hiddemann; Hans-Jochem Kolb
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Blood 2006;108(3):1092-9.
2006: Thorsten Zenz; Gerhard Glatting; Richard F Schlenk; Inga Buchmann; Hartmut Döhner; Sven N Reske; Donald Bunjes
Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
Haematologica 2006;91(2):285-6.
2006: Thorsten Zenz; Richard F Schlenk; Gerhard Glatting; Bernd Neumaier; Norbert M Blumstein; Inga Buchmann; Stephanie von Harsdorf; Mark Ringhoffer; Markus Wiesneth; Frieder Keller; Jörg Kotzerke; Erwin M Röttinger; Stephan Stilgenbauer; Hartmut Döhner; Sven N Reske; Donald Bunjes
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(2):278-86.
2006: Gerhard Glatting; Thomas Kull; Norbert M Blumstein; Donald Bunjes; Bernd Neumaier; Andreas K Buck; Sven N Reske
Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.
Nuklearmedizin. Nuclear medicine 2006;45(3):134-8.
2005: Georg Hess; Donald Bunjes; Wolfgang Siegert; Rainer Schwerdtfeger; Georg Ledderose; Barbara Wassmann; Guido Kobbe; Martin Bornhäuser; Andreas Hochhaus; Andrew J Ullmann; Thomas Kindler; Ulrike Haus; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7583-93.
2005: Mark Ringhoffer; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Stephanie von Harsdorf; Inga Buchmann; Markus Wiesneth; Jörg Kotzerke; Thorsten Zenz; Andreas K Buck; Peter Schauwecker; Stephan Stilgenbauer; Hartmut Döhner; Sven N Reske; Donald Bunjes
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
British journal of haematology 2005;130(4):604-13.
2005: Barbara Wassmann; Heike Pfeifer; Michael Stadler; Martin Bornhaüser; Gesine Bug; Urban J Scheuring; Patrick Brück; Matthias Stelljes; Rainer Schwerdtfeger; Nadezda Basara; Jolanta B Perz; Donald Bunjes; Georg Ledderose; Rolf Mahlberg; Anja Binckebanck; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2005;106(2):458-63.
2005: Laurent Garderet; Myriam Labopin; Norbert-Claude Gorin; Emmanuelle Polge; André Baruchel; Giovanna Meloni; Juan Ortega; Jaak Vossen; Donald Bunjes; Guy Leverger; Didier Blaise; Augustin Ferrant; Mats Brune; Eric Dore; Helmut Gadner; Felix Zintl; Isaac Yaniv; Giorgio Dini; Francesco Frassoni
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Blood 2005;105(1):405-9.
2004: Matthias Ritgen; Stephan Stilgenbauer; Nils von neuhoff; Andreas Humpe; Monika Brüggemann; Christiane Pott; Thorsten Raff; Alexander Kröber; Donald Bunjes; Richard F Schlenk; Norbert Schmitz; Hartmut Döhner; Michael Kneba; Peter Dreger
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
Blood 2004;104(8):2600-2.
2004: Mark Ringhoffer; Markus Wiesneth; Stephanie von Harsdorf; Richard F Schlenk; Anita Schmitt; Peter Reinhardt; Margit Moessner; Wolfgang Grimminger; Thomas Mertens; Sven N Reske; Hartmut Döhner; Donald Bunjes
CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.
British journal of haematology 2004;126(4):527-35.
2004: Ulrich Vogel; Heike Claus; Lutz Von Müller; Donald Bunjes; Johannes Elias; Matthias Frosch
Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl).
Journal of clinical microbiology 2004;42(7):2898-901.
2003: Sylvia Stracke; Udo Helmchen; Lutz Von Müller; Donald Bunjes; Frieder Keller
Polyoma virus-associated interstitial nephritis in a patient with acute myeloic leukaemia and peripheral blood stem cell transplantation.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(11):2431-3.
2003: Erwin M Röttinger; Detlef Bartkowiak; Donald Bunjes; Roman Wennauer; Dagmar Dohr
Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2003;179(10):702-7.
2003: Thorsten Zenz; Hartmut Döhner; Donald Bunjes
Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.
Bone marrow transplantation 2003;32(4):437-8.
2003: Petra Gottlöber; Ulrike Leiter; W Friedrich; Donald Bunjes; A Schulz; Martina Kerscher; Ralf Uwe Peter
Chronic cutaneous sclerodermoid graft-versus-host disease: evaluation by 20-MHz sonography.
Journal of the European Academy of Dermatology and Venereology : JEADV 2003;17(4):402-7.
2003: Markus Ditschkowski; Hermann Einsele; Rainer Schwerdtfeger; Donald Bunjes; Rudolf Trenschel; Dietrich W Beelen; Ahmet H Elmaagacli
Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation.
Transplantation 2003;75(10):1745-7.
2003: Inga Buchmann; Thomas Kull; Gerhard Glatting; Donald Bunjes; Geoffrey Hale; Jörg Kotzerke; Dirk Rattat; Hartmut Dohner; Sven N Reske
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
European journal of nuclear medicine and molecular imaging 2003;30(5):667-73.
2002: Olle Ringdén; Myriam Labopin; Andrea Bacigalupo; William Arcese; UW Schaefer; Rein Willemze; H Koc; Donald Bunjes; E Gluckman; Vanderson Rocha; Antonius V M B Schattenberg; Francesco Frassoni
Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4655-64.
2002: Donald Bunjes
188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
Leukemia & lymphoma 2002;43(11):2125-31.
2002: Ulrike Leiter; Peter Kaskel; Gertraud Krähn; Petra Gottlöber; Donald Bunjes; Ralf Uwe Peter; Martina Kerscher
Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease.
Photodermatology, photoimmunology & photomedicine 2002;18(4):183-90.
2002: cesare guglielmi; William Arcese; Francesco Dazzi; Ronald Brand; Donald Bunjes; Leo F Verdonck; Anton Schattenberg; Hans-Jochem Kolb; Per Ljungman; Agnès Devergie; Andrea Bacigalupo; Marta Gomez; Mauricette Michallet; Ahmet H Elmaagacli; Alois Gratwohl; Jane Apperley; Dietger Niederwieser
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.
Blood 2002;100(2):397-405.
2002: Inga Buchmann; Donald Bunjes; Jörg Kotzerke; Hans Martin; Gerhard Glatting; Ulrike Seitz; Dirk Rattat; Andreas Buck; Hartmut Döhner; Sven N Reske
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Cancer biotherapy & radiopharmaceuticals 2002;17(2):151-63.
2002: Holger Schirrmeister; Martin Bommer; Andreas K Buck; S Müller; PM Messer; Donald Bunjes; Hartmut Döhner; Lothar Bergmann; Sven N Reske
Initial results in the assessment of multiple myeloma using 18F-FDG PET.
European journal of nuclear medicine and molecular imaging 2002;29(3):361-6.
2001: Mark Ringhoffer; Konstanze Döhner; S Scheil; Heike Wilts; Thomas Mertens; Wolfgang Grimminger; Hartmut Döhner; Donald Bunjes
Fatal outcome in a patient developing Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease.
Bone marrow transplantation 2001;28(6):615-8.
2001: Donald Bunjes; Inga Buchmann; C Duncker; Ulrike Seitz; Jörg Kotzerke; Markus Wiesneth; Dagmar Dohr; Martin Stefanic; Andreas Buck; Stephanie von Harsdorf; Gerhard Glatting; Wolfgang Grimminger; T Karakas; Gerd Munzert; Hartmut Döhner; Lothar Bergmann; Sven N Reske
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Blood 2001;98(3):565-72.
2001: Sven N Reske; Donald Bunjes; Inga Buchmann; Ulrike Seitz; Gerhard Glatting; Bernd Neumaier; Jörg Kotzerke; Andreas Buck; H Martin; Hartmut Döhner; Lothar Bergmann
Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.
European journal of nuclear medicine 2001;28(7):807-15.
2001: Inga Buchmann; Michael Reinhardt; K Elsner; Donald Bunjes; Carsten Altehoefer; J Finke; E Moser; Gerhard Glatting; Jörg Kotzerke; CA Guhlmann; Holger Schirrmeister; Sven N Reske
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Cancer 2001;91(5):889-99.
2001: Donald Bunjes
The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML.
Cytotherapy 2001;3(3):175-88.
2001: Geoff Hale; Stephen P Cobbold; Nicolas Novitzky; Donald Bunjes; R Willemze; H G Prentice; D Milligan; S MacKinnon; Herman Waldmann
CAMPATH-1 antibodies in stem-cell transplantation.
Cytotherapy 2001;3(3):145-64.
2000: Donald Bunjes
T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
Transfusion science 2000;23(2):151-62.
2000: Geoff Hale; P Jacobs; L Wood; W E Fibbe; R Barge; Nicolas Novitzky; C Toit; Louise Abrahams; Valda Thomas; Donald Bunjes; C Duncker; Markus Wiesneth; D Selleslag; M Hidajat; M Starobinski; P Bird; Herman Waldmann
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Bone marrow transplantation 2000;26(1):69-76.
2000: C Duncker; Dagmar Dohr; Stephanie von Harsdorf; Justus Duyster; Martin Stefanic; C Martini; M Treiber; Bernd Hertenstein; J Novotny; R Arnold; Hermann Heimpel; Lothar Bergmann; Donald Bunjes
Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome.
Bone marrow transplantation 2000;25(12):1263-8.
2000: cesare guglielmi; William Arcese; J Hermans; A Bacigalupo; Giuseppe Bandini; Donald Bunjes; E Carreras; Agnès Devergie; F Frassoni; J Goldman; A Gratwohl; Hans-Jochem Kolb; Anna Paola Iori; Dietger Niederwieser; H G Prentice; T de Witte; Jane Apperley
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Blood 2000;95(11):3328-34.
2000: Donald Bunjes; C Duncker; Markus Wiesneth; Martin Stefanic; Dagmar Dohr; Stephanie von Harsdorf; T Karakas; Sven N Reske; Lothar Bergmann
CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation.
Bone marrow transplantation 2000;25 Suppl 2():S9-11.
2000: Jörg Kotzerke; Gerhard Glatting; Ulrike Seitz; M Rentschler; Bernd Neumaier; Donald Bunjes; C Duncker; Dagmar Dohr; Lothar Bergmann; Sven N Reske
Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(3):531-7.
1999: Ulrike Seitz; Bernd Neumaier; Gerhard Glatting; Jörg Kotzerke; Donald Bunjes; Sven N Reske
Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
European journal of nuclear medicine 1999;26(10):1265-73.
1999: Markus Wiesneth; T Schreiner; Donald Bunjes; C Bischof; E Erne; B Maccari; B Kubanek
Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse.
Journal of hematotherapy 1999;8(3):269-74.
1998: Geoff Hale; M J Zhang; Donald Bunjes; H G Prentice; D Spence; M M Horowitz; A J Barrett; Herman Waldmann
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Blood 1998;92(12):4581-90.
1998: Martin Griesshammer; R Arnold; Markus Bangerter; M Hafner; Barbara Heinze; Bernd Hertenstein; Hermann Heimpel; Donald Bunjes
Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients.
European journal of haematology 1998;61(1):7-13.
1998: Markus Wiesneth; T Schreiner; Wilhelm Friedrich; Donald Bunjes; C Duncker; E Krug; B Maccari; S Müller; S Nowak; B Kubanek
Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation.
Bone marrow transplantation 1998;21 Suppl 3():S21-4.
1996: O Prümmer; Donald Bunjes; Markus Wiesneth; B Hertenstein; Rudolf Arnold; Franz Porzsolt; Hermann Heimpel
Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation.
Bone marrow transplantation 1996;17(4):617-23.
1995: B Hertenstein; B Wagner; Donald Bunjes; C Duncker; A Raghavachar; Rudolf Arnold; Hermann Heimpel; Hubert Schrezenmeier
Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
Blood 1995;86(4):1487-92.
1995: Donald Bunjes; Matthias Theobald; T Nierle; Rudolf Arnold; Hermann Heimpel
Presence of host-specific interleukin 2-secreting T helper cell precursors correlates closely with active primary and secondary chronic graft-versus-host disease.
Bone marrow transplantation 1995;15(5):727-32.
1995: Donald Bunjes; Matthias Theobald; B Hertenstein; Markus Wiesneth; J Novotny; Rudolf Arnold; Hermann Heimpel
Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.
Bone marrow transplantation 1995;15(5):713-9.
1995: Donald Bunjes; B Hertenstein; Markus Wiesneth; M Stefanic; J Novotny; C Duncker; W Heit; Rudolf Arnold; Hermann Heimpel
In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate.
Bone marrow transplantation 1995;15(4):563-8.
1995: B Hertenstein; Walter Hampl; Donald Bunjes; Markus Wiesneth; C Duncker; Ulrich H Koszinowski; Hermann Heimpel; Rudolf Arnold; Thomas Mertens
In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.
Bone marrow transplantation 1995;15(3):387-93.
1994: B Hertenstein; M Stefanic; Michael Sandherr; Donald Bunjes; T Mertens; Rudolf Arnold
Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).
Transplantation proceedings 1994;26(6):3114-6.
1994: O Prümmer; Donald Bunjes; Markus Wiesneth; Rudolf Arnold; Franz Porzsolt; Hermann Heimpel
High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Bone marrow transplantation 1994;14(3):483-6.
1994: Gerhard Heil; Jürgen Krauter; E Beyer-Johannböke; Donald Bunjes; E Kurrle; C Westphal-Frösch; Hermann Heimpel
CD 54 expression and its role in homotypic aggregation of the blasts of acute myeloblastic leukemias (AML).
International journal of hematology 1994;60(1):39-49.
1994: B Hertenstein; M Stefanic; T Schmeiser; M Scholz; V Göller; Malte Clausen; Donald Bunjes; Markus Wiesneth; J Novotny; Matthias Kochs
Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(5):998-1004.
1994: Norbert Frickhofen; Markus Wiesneth; C Jainta; B Hertenstein; B Heymer; L Bianchi; H P Dienes; K Koerner; Donald Bunjes; Rudolf Arnold
Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation.
Blood 1994;83(7):1998-2004.
1994: Markus Wiesneth; B Hertenstein; Donald Bunjes; J Novotny; M Stefanic; Barbara Heinze; T Schreiner; B Kubanek; Hermann Heimpel; Rudolf Arnold
[Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine 1994;32():276-80.
1994: B Hertenstein; Winfried V Kern; T Schmeiser; M Stefanic; Donald Bunjes; Markus Wiesneth; J Novotny; Hermann Heimpel; Rudolf Arnold
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia.
Annals of hematology 1994;68(1):21-6.
1993: B Hertenstein; Markus Wiesneth; J Novotny; Donald Bunjes; M Stefanic; Barbara Heinze; G Hübner; Hermann Heimpel; Rudolf Arnold
Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Transplantation 1993;56(5):1114-8.
1993: Donald Bunjes; Matthias Theobald; Markus Wiesneth; Hubert Schrezenmeier; T Hoffmann; B Hertenstein; Rudolf Arnold; Hermann Heimpel
Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation.
Bone marrow transplantation 1993;12(3):209-15.
1993: T Hoffmann; Matthias Theobald; Donald Bunjes; M Weiss; Hermann Heimpel; W Heit
Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells.
Bone marrow transplantation 1993;12(1):1-8.
1993: Matthias Theobald; Donald Bunjes
Pretransplant detection of human minor histocompatibility antigen-specific naive and memory interleukin-2-secreting T cells within class I major histocompatibility complex (MHC)-restricted CD8+ and class II MHC-restricted CD4+ T-cell subsets.
Blood 1993;82(1):298-306.
1993: Rudolf Arnold; Johannes W G Janssen; Barbara Heinze; Donald Bunjes; B Hertenstein; Markus Wiesneth; B Kubanek; Hermann Heimpel; Claus R Bartram
Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.
Leukemia 1993;7(5):747-51.
1993: T Nierle; Donald Bunjes; Rudolf Arnold; Hermann Heimpel; Matthias Theobald
Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation.
Blood 1993;81(3):841-8.
1993: Matthias Theobald; Donald Bunjes; T Nierle; Rudolf Arnold; Hermann Heimpel
Measurement of recipient-specific alloreactivity: is GVHD predictable?
Bone marrow transplantation 1993;12 Suppl 3():S18-23.
1993: Rudolf Arnold; Donald Bunjes; Markus Wiesneth; B Hertenstein; Matthias Theobald; Hermann Heimpel; G Hale; H Waldmann
In vitro and in vivo depletion of T cells.
Bone marrow transplantation 1993;12 Suppl 3():S11-2.
1992: Matthias Theobald; T Nierle; Donald Bunjes; Rudolf Arnold; Hermann Heimpel
Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings.
The New England journal of medicine 1992;327(23):1613-7.
1992: Markus Wiesneth; B Hertenstein; Donald Bunjes; T Schmeiser; B Maccari; H Northoff; H Laasch; W Heit; R Arnold; Hermann Heimpel
ABO-incompatible bone marrow transplantation.
Beiträge zur Infusionstherapie = Contributions to infusion therapy 1992;30():354-8.
1991: Barbara Heinze; Rudolf Arnold; E Kratt; Donald Bunjes; K Reess; P Plecity; Hermann Heimpel; Theodor M Fliedner
Kinetics of relapse of leukemia after bone marrow transplantation: cytogenetic follow up of patients with chronic myelogenous leukemia.
Bone marrow transplantation 1991;7 Suppl 2():16.
1990: Matthias Theobald; T Hoffmann; Donald Bunjes; W Heit
Frequency, specificity, and phenotype of clonally growing human alloreactive interleukin-2-secreting helper T lymphocyte precursors.
Transplantation 1990;50(5):850-6.
1990: Donald Bunjes; Markus Wiesneth; B Hertenstein; T Schmeiser; Rudolf Arnold; W Heit
Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy.
Bone marrow transplantation 1990;6(5):309-14.
1990: Matthias Theobald; T Hoffmann; Donald Bunjes; W Heit
Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy, and the monoclonal antibody Campath-1G, using limiting dilution methodology.
Transplantation 1990;49(3):553-9.
1989: T Schmeiser; Markus Wiesneth; Donald Bunjes; Rudolf Arnold; B Hertenstein; W Heit; E Kurrle
Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow.
Infection 1989;17(3):124-30.
1988: Markus Wiesneth; B Hertenstein; Donald Bunjes; T Schmeiser; Rudolf Arnold; Hermann Heimpel; W Heit
T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.
European journal of haematology 1988;41(3):243-9.
1988: T Schmeiser; Rudolf Arnold; Markus Wiesneth; B Hertenstein; Donald Bunjes; B Anger; W Heit; Hermann Heimpel
[Bone marrow transplantation as therapy in chronic myeloid leukemia].
Deutsche medizinische Wochenschrift (1946) 1988;113(1):6-10.
1988: T Schmeiser; E Kurrle; Rudolf Arnold; Markus Wiesneth; Donald Bunjes; B Hertenstein; Wolfgang Kern; W Heit; H Heimpel
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Scandinavian journal of infectious diseases 1988;20(6):625-31.
1987: T Schmeiser; W Heit; Rudolf Arnold; Donald Bunjes; Markus Wiesneth; B Hertenstein; Walter Hampl; Hermann Heimpel
Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.
Klinische Wochenschrift 1987;65(20):967-74.
1987: Donald Bunjes; W Heit; R Arnold; T Schmeiser; Markus Wiesneth; F Carbonell; F Porzsolt; A Raghavachar; H Heimpel
Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts.
Transplantation 1987;43(4):501-5.
1986: W Heit; Donald Bunjes; Markus Wiesneth; T Schmeiser; R Arnold; G Hale; H Waldmann; H Heimpel
Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
British journal of haematology 1986;64(3):479-86.
1986: Donald Bunjes; W Heit; R Arnold; T Schmeiser; H Heimpel
Cyclosporine as an alternative to cyclophosphamide in the treatment of chronic graft-versus-host disease.
Transplantation 1986;41(2):170-2.
1985: Norbert Frickhofen; W Heit; Donald Bunjes; H Heimpel
Graft rejection after syngeneic bone marrow transplantation for aplastic anaemia: significance of coculture studies.
British journal of haematology 1985;59(1):183-5.